fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Norfloxacin

All products: not a benefit

Noroxin · DIN 00643025 · 400 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-06-18 — choose a marketed DIN from the same-category list.Discontinued June 18, 2005 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-06-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-06-18 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Noroxin · DIN 00643025 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 1996-10-01 Daily cost (source): $3.7172 Health Canada: Cancelled post market since 2005-06-18 · brand NOROXIN · ATC J01MA06 NORFLOXACIN · form Tablet · route Oral · ingredients NORFLOXACIN 400 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Noroxin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00643025)

Source record
DIN 00643025: Noroxin Raw flags: notABenefit=Y, sec3=Y Item: 084000010; group id 138; item number 0231; lccId None; manufacturer id MSD Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00643025 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6866
Interchangeable products
Norfloxacin · DIN 02229524 · $1.8586
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00643025
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 18, 2005 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01MA): coverage varies; not interchangeable

  • Ciprofloxacin (Cipro): general benefit, limited Use 533, not a benefit
  • Levofloxacin (Levaquin): general benefit, not a benefit
  • Moxifloxacin (Avelox): general benefit, not a benefit
  • Ciprofloxacin + ciprofloxacin base (Cipro XL): limited Use 394, not a benefit
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 7 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS NORFLOXACIN (norfloxacin tablets) is indicated for:  The treatment of upper and lower urinary tract infections, specifically complicated and uncomplicated cystitis, pyelitis and pyelonephritis caused by susceptible strains of the following microorganisms:  Escherichia coli  Klebsiella pneumonia  unspecified Klebsiella spp.  unspecified Enterobacter spp.  unspecified Citrobacter spp.  Proteus mirabilis  Staphylococcus aureus  Streptococcus faecalis  Pseudomonas aeruginosa  The treatment of adults with gonococcal urethritis, or cervicitis due to penicillinase producing and non-penicillinase producing Neisseria gonorrhoeae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of NORFLOXACIN and other antibacterial drugs, NORFLOXACIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data… https://pdf.hres.ca/dpd_pm/00080787.PDF PM date: JUL 16, 1998 Source product: NORFLOXACIN; DIN 02229524; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Noroxin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026